★Neurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move.

Strategic Analysis // Ian Gross

"This potential acquisition signals a major pharmaceutical player is aggressively entering the booming obesity drug market. It highlights the sector's intense competition and the significant capital flowing into developing new weight-loss treatments, impacting drug developers and healthcare investors alike."

Human-Vetted Professional Intelligence

The Big Market Report Take

Looks like Neurocrine is jumping into the obesity drug race, and they're doing it the quick way: buying Soleno. Soleno's stock is understandably happy about the news. Smart move if they think they can get a head start.

Read full article on MarketWatch Back to today's briefing

Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →

Never miss a story

★Neurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move.

More from this section